Previous clinical studies in melanoma, gastric cancer, and head/neck cancer have shown that the mRNA profiles of the above‐mentioned genes can predict the response to PD‐1 blockade.[17] Our data revealed that BCG treatment significantly upregulated the expression of all those IFN‐γ signaling genes (Figure 4C). The gene discussed is PDCD1; the disease is melanoma.